LON:AMYT - Amryt Pharma Stock Price, News, & Analysis

GBX 12.38
0.00 (0.00 %)
(As of 07/19/2019 04:00 PM ET)
Today's Range
Now: GBX 12.38
50-Day Range
MA: GBX 13.61
52-Week Range
Now: GBX 12.38
Average Volume184,629 shs
Market Capitalization£5.67 million
P/E RatioN/A
Dividend YieldN/A
Amryt Pharma plc, a commercial stage pharmaceutical company, focuses on the acquisition, development, and commercialization of medicines for the treatment of rare and orphan diseases. The company operates through two segments, Commercial and Research and Development. It offers Lojuxta (lomitapide), a drug used to treat a rare life-threatening disease Homozygous Familial Hypercholesterolaemia; and a range of dermo cosmetic products under the Imlan brand. Read More…

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic



Sales & Book Value

Annual SalesN/A
Book ValueGBX 4.60 per share



Market Cap£5.67 million
Next Earnings Date9/23/2019 (Estimated)
OptionableNot Optionable

Receive AMYT News and Ratings via Email

Sign-up to receive the latest news and ratings for AMYT and its competitors with MarketBeat's FREE daily newsletter.

Amryt Pharma (LON:AMYT) Frequently Asked Questions

What is Amryt Pharma's stock symbol?

Amryt Pharma trades on the London Stock Exchange (LON) under the ticker symbol "AMYT."

When is Amryt Pharma's next earnings date?

Amryt Pharma is scheduled to release their next quarterly earnings announcement on Monday, September 23rd 2019. View Earnings Estimates for Amryt Pharma.

Has Amryt Pharma been receiving favorable news coverage?

News coverage about AMYT stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Amryt Pharma earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Amryt Pharma.

Who are some of Amryt Pharma's key competitors?

What other stocks do shareholders of Amryt Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include Chubb (CB), The Parkmead Group (PMG), Himax Technologies (HIMX), Atalaya Mining (ATYM), Concepta (CPT), Faroe Petroleum (FPM), Vectura Group (VEC), Xcite Energy (XEL), BK IRELAND GRP/ADR (BKRIY) and BowLeven (BLVN).

Who are Amryt Pharma's key executives?

Amryt Pharma's management team includes the folowing people:
  • Dr. Joseph Wiley, Founder, CEO & Exec. Director (Age 48)
  • Mr. Rory Nealon, CFO, COO, Company Sec. & Exec. Director (Age 51)
  • Dr. Tobias Zahn, Head of Clinical Operations
  • Dr. Mark Sumeray, Chief Medical Officer (Age 53)
  • Mr. David Allmond, Chief Commercial Officer

How do I buy shares of Amryt Pharma?

Shares of AMYT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Amryt Pharma's stock price today?

One share of AMYT stock can currently be purchased for approximately GBX 12.38.

How big of a company is Amryt Pharma?

Amryt Pharma has a market capitalization of £5.67 million. Amryt Pharma employs 41 workers across the globe.View Additional Information About Amryt Pharma.

What is Amryt Pharma's official website?

The official website for Amryt Pharma is http://www.amrytpharma.com/.

How can I contact Amryt Pharma?

Amryt Pharma's mailing address is Ivybridge House, 1 Adam Street, LONDON, WC2N 6LE, United Kingdom. The company can be reached via phone at +44-20-34155730.

MarketBeat Community Rating for Amryt Pharma (LON AMYT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  191 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  400
MarketBeat's community ratings are surveys of what our community members think about Amryt Pharma and other stocks. Vote "Outperform" if you believe AMYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2019 by MarketBeat.com Staff

Featured Article: What is a management fee?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel